14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DAWN vs ANL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DAWN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)
DAWN Overall Winner
6-Pillar Tally: DAWN 4 – 1 ANL (1 Tie)
Matrix Metrics: DAWN 6 – 2 ANL
As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over ANL (ANL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DAWN carries a Unified Composite Score of 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin), whereas ANL carries 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin).
Growth vs. Quality Trade-Off: DAWN earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. ANL 48.3/100 HOLD) and 0.03β · 2% Vol risk profile, whereas ANL leads top-line expansion (+178.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DAWN vs ANL. Trailing 12-month operating profitability (DAWN -51.1% vs ANL -123.5%) and valuation multiples (DAWN N/M vs ANL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $677.5M market capitalization and -123.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DAWN vs ANL Key Questions & Quantitative Answers
As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over ANL (ANL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DAWN carries a Unified Composite Score of 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin), whereas ANL carries 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin). Growth vs. Quality Trade-Off: DAWN earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. ANL 48.3/100 HOLD) and 0.03β · 2% Vol risk profile, whereas ANL leads top-line expansion (+178.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DAWN leads the Growth & Scale pillar: DAWN posts +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin), compared with ANL at +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin). On trailing 12-month operating scale, DAWN generates $158M in USD-normalized revenue versus $18M for ANL. In operating R&D and SG&A reinvestment, DAWN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANL.
DAWN screens cheaper on headline valuation multiples. DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin), whereas ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.5x EV/Revenue (-119.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DAWN (-22.7% ROE) versus ANL (-20.2% ROE) capital efficiency.
In options market volatility and institutional positioning, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk). By comparison, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.